Last reviewed · How we verify
exenatide/insulin glargine — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
exenatide/insulin glargine (exenatide/insulin glargine) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| exenatide/insulin glargine TARGET | exenatide/insulin glargine | AstraZeneca | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- exenatide/insulin glargine CI watch — RSS
- exenatide/insulin glargine CI watch — Atom
- exenatide/insulin glargine CI watch — JSON
- exenatide/insulin glargine alone — RSS
Cite this brief
Drug Landscape (2026). exenatide/insulin glargine — Competitive Intelligence Brief. https://druglandscape.com/ci/exenatide-insulin-glargine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab